Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589227 | 1.00 | HPGD (0.34) | HPGDRECQLHTTALDH1A1KDM4E | |
| SCHEMBL21224540 | 0.78 | TSHR (0.41) | HPGDALDH1A1KDM4EHSD17B10MAPT | |
| Nitrous Acid SCHEMBL28022168 | 0.73 | KDM4C (0.39) | RECQLHTTALDH1A1KDM4EMAPT | |
| SCHEMBL70537 | 0.68 | HCAR2 (0.46) | HPGDALDH1A1KDM4EALOX15MAPT | |
| SCHEMBL16738021 | 0.67 | ALDH1A1 (0.55) | HTTALDH1A1ALOX15MAPTRAB9A | |
| SCHEMBL26601379 | 0.67 | KDM4E (0.42) | HPGDRECQLHTTALDH1A1KDM4E | |
| SCHEMBL26601381 | 0.67 | KDM4E (0.42) | HPGDRECQLHTTALDH1A1KDM4E | |
| SCHEMBL1465976 | 0.65 | PTGS2 (0.42) | HTTALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL1465972 | 0.65 | PTGS2 (0.42) | HTTALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL1465974 | 0.65 | PTGS2 (0.42) | HTTALDH1A1KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| EP-3959214-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | HPGD 1605/4885RECQL 1627/4885HTT 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.